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ABSTRACT 
Purpose: Coffee and tea constituents have shown several anti-carcinogenic activities in 
cellular and animal studies, including against thyroid cancer (TC). However, epidemiological 
evidence is still limited and inconsistent. Therefore, we aimed to investigate this association 
in a large prospective study. 
Methods: The study was conducted in the EPIC (European Prospective Investigation into 
Cancer and Nutrition) cohort, which included 476,108 adult men and women. Coffee and tea 
intakes were assessed through validated country-specific dietary questionnaires.  
Results: During a mean follow-up of 14 years, 748 first incident differentiated TC cases 
(including 601 papillary and 109 follicular TC) were identified. Coffee consumption (per 
100mL/day) was not associated either with total differentiated TC risk (HRcalibrated=1.00, 95% 
CI 0.97-1.04) or with the risk of TC subtypes. Tea consumption (per 100mL/day) was not 
associated with the risk of total differentiated TC (HRcalibrated=0.98, 95% CI 0.95-1.02) and 
papillary tumor (HRcalibrated=0.99, 95% CI 0.95-1.03); whereas an inverse association was 
found with follicular tumor risk (HRcalibrated=0.90, 95% CI 0.81-0.99), but this association was 
based on a sub-analysis with a small number of cancer cases. 
Conclusions: In this large prospective study, coffee and tea consumptions were not associated 
with TC risk. . 
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INTRODUCTION 
Thyroid cancer (TC) is considered the most common endocrine cancer, and its incidence has 
been continuously increasing in the last decades [1], especially due to over-diagnosis [2]. In 
Europe, the number of new TC cases in 2012 was 53,000 and it is usually 3-fold more 
common in women than in men [3]. Differentiated TC, including papillary and follicular 
carcinoma, represents 90% of TC [4]. Only few risk factors have been well-established for 
TC, such as history of having a benign thyroid tumor, exposure to ionizing radiation in 
childhood, and body fatness [4,5]. Dietary factors, such as nutrients and components (e.g., 
energy, polyunsaturated fatty acids, alcohol, and flavonoids) [6-8] and foods (e.g., fish, fruits 
and vegetables, coffee and tea) [9-12], have been suggested to play a role in TC etiology, 
although until now epidemiological evidence is still very limited and inconclusive [4]. 
After water, coffee and tea are the most consumed beverages worldwide in adults [13]. Tea 
and coffee are rich sources of flavonoids and phenolic acids, respectively [14]. Basic research 
has shown that these polyphenol classes may play a role in cancer prevention, including TC 
[15], through the modulation of enzyme activities and signal transduction pathways related to 
cellular proliferation, differentiation, apoptosis, inflammation, angiogenesis and metastasis 
[16,17]. However, other coffee and tea constituents, such as caffeine and theophylline, have 
shown both negative and positive effects in carcinogenesis [18]. Epidemiological evidence on 
the association between coffee and tea intake and TC risk is limited; a protective association 
on tea consumption and TC risk was observed in a recent meta-analysis [11], while no 
association was found with coffee intake in another meta-analysis [12]. Those results need to 
be interpreted with caution because of potential biases, since most of the studies published so 
far were case-control studies and included a small number of TC cases. Therefore, further 
large cohort studies are warranted. 
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In the current study, we aimed to investigate the relationships between coffee and tea 
consumption, and the risk of differentiated TC within the European Prospective Investigation 
into Cancer and Nutrition (EPIC), a large cohort with a relatively high number of TC cases 
and a wide variability in the intake of these beverages.  
 
MATERIAL AND METHODS 
Study population 
EPIC is an ongoing multi-center cohort study aimed to evaluate the associations between 
dietary, lifestyle and genetic factors and cancer risk. The study enrolled 521,324 subjects 
(70.1% women) between 1992 and 2000, mostly aged between 35-70 years, from 23 centers 
in 10 European countries (Denmark, France, Germany, Greece, Italy, the Netherlands, 
Norway, Spain, Sweden, and United Kingdom). The participants were mostly chosen from the 
general population with some exceptions. Further details of the study have been previously 
described [19]. The study was performed in accordance with the Declaration of Helsinki. 
Moreover, the ethical approval was provided from the review boards of the International 
Agency for Research on Cancer and local participating centers. Written informed consent was 
also provided by all study participants. Exclusions before the beginning of the analyses 
included: participants with missing or null follow-up time or having a prevalent cancer other 
than non-melanoma skin cancer at baseline (n =29,332); participants with incomplete 
information on lifestyle (n =1,277); and participants with dietary data unavailable or 
considered to be implausible (i.e. participants in the highest and lowest 1% of the distribution 
for the ratio between energy intake to estimated energy requirement, n= 14,555). Therefore, 
our analysis included 476,108 participants (333,876 women and 142,232 men).  
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Dietary and lifestyle assessment 
At enrollment, dietary information over the previous 12 months was collected using 
country/center specific dietary questionnaires [19]. The relative validity and reproducibility of 
these questionnaires has been previously published [20]. In all countries, dietary 
questionnaires were self-reported, except in in Ragusa and Naples (Italy), Greece and Spain, 
where they were administered by trained interviewers. In Norway, data on tea consumption 
were not collected. Data on consumption of coffee type, i.e. caffeinated and decaffeinated, 
were only specified in some centers [France, Germany, Greece, Italy (Florence, Varese and 
Turin only), the Netherlands and the United Kingdom]. A standardized computerized 24-h 
dietary recall was used to obtain a second dietary measurement (between 1995 and 1999) 
from a random sample of the cohort (n=36,994) to calibrate dietary measurements across 
countries and to correct for systematic over- or under-estimation of dietary intakes [21]. The 
quantity of coffee and tea intake was converted from cups per month, week or day in the 
dietary questionnaires into mL/day using the typical sizes of tea/coffee cups for each center. 
Lifestyle questionnaires were used to obtain information on education (used as a proxy for 
socioeconomic status), smoking status and intensity, alcohol consumption, physical activity 
levels [22], oral contraceptive use, menopausal status, and menopausal hormone use. 
Anthropometry (weight and height) was measured at recruitment by trained personnel, with 
the exception of Oxford (United Kingdom), Norway, and France, where measurements were 
self-reported [19]. 
Follow-up and case ascertainment  
Incident cancer cases were identified through population cancer registries in all countries 
except France, Germany and Greece where cases were identified through active follow-up, 
directly from the participants or next of kin, and confirmed by a combination of methods, 
such as health insurance records, and cancer and pathology registries. Mortality data were 
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obtained from mortality registries at the regional or national level. Complete follow-up 
censoring dates ranged from December 2010 to December 2014, depending on the study 
centre. 
The 10th Revision of the International Statistical Classification of Diseases, Injuries, and 
Causes of Death (ICD-10) was used to code TC (code C73). In this analysis only 
differentiated TC cases were included, and therefore, of the 800 TC cases ascertained, 
anaplastic (n=9), medullary (n=37), lymphoma (n=1) forms, and “other morphologies” (n=5) 
of TC cases were excluded. Finally, 748 first primary incident differentiated TC cases were 
considered: 601 papillary TCs, 109 follicular TCs, and 38 not otherwise specified (NOS) TCs, 
most likely to be papillary TCs. 
Statistical analysis 
Cox proportional hazard models were used to estimate hazard ratios (HR) and 95% 
confidence intervals (CI) between coffee and tea consumption and differentiated TC risk. 
Intakes of coffee and tea were analyzed as continuous variables (increments of 100 mL/day). 
Coffee consumers were also analyzed using cohort-wide quartiles. Due to the high percentage 
of tea non-consumers (33.9%), individual tea consumption was classified as non-consumers, 
and cohort-wide tertiles established among consumers. Tests for linear trend were performed 
by attributing the median of each category as score. Age was the primary time variable in all 
models. Entry time was age at recruitment and exit time was age at first diagnosis of any type 
of cancer, death, or censoring date (loss or end of follow-up), whichever occurred first. Tests 
and graphs based on Schoenfeld residuals were used to assess proportional hazards 
assumptions, which were satisfied. The basic model (model 1) was stratified by sex, age at 
recruitment (1-year interval) and center. The multivariable model (model 2) was additionally 
adjusted for body mass index (BMI, continuous variable in kg/m
2
), smoking status (never, 
former, current smoker and unknown), alcohol consumption (g/day), education level 
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(primary, secondary and unknown), physical activity (inactive, active and unknown according 
to the Cambridge Physical Activity Index) [22], and total energy intake (kcal/day). In women, 
model 2 was also adjusted for menopausal status and type (pre-, peri-, post-, and surgical 
menopause), ever use of oral contraceptives (yes, no and unknown), and history of infertility 
problems (yes, no and unknown). 
Separate analyses were performed for differentiated TC subtypes: follicular and papillary 
tumors. Heterogeneity of risk between TC subtypes was assessed with the Wald test [23]. 
Possible interactions of coffee/tea consumption with sex, body mass index (categorical 
variable: BMI<25 and BMI≥25), tobacco smoking status (never, former, and current 
smokers), and physical activity (inactive and active) were tested by including an interaction 
term in the multi-adjusted models. Separate BMI-specific models were fitted because a 
significant interaction between BMI categories (BMI<25 and BMI≥25) and coffee intake was 
detected. Sensitivity analyses were performed by repeating the models after the exclusion of 
differentiated TC cases diagnosed during the first 2 years of follow-up, since participants may 
have changed their diets in the pre-diagnostic period. Finally, we also conducted analyses 
using country-specific levels of coffee consumption instead of overall cohort-wide levels of 
consumption, because coffee volumes and compositions notably differed among EPIC 
countries. For all analyses, p-values <0.05 were considered as statistically significant. 
Statistical analyses were conducted by using SAS, version 9.3, software (SAS Institute). 
Calibration of dietary data 
A calibration method was used to correct for between-center errors and to correct for random 
and systematic within-person errors. In this method, the 24-HDR values of 36,994 
participants were regressed on the main dietary questionnaire values for coffee and tea with 
adjustment for age at recruitment, center, and total energy intake, and weighting by day of the 
week and season of the year during which the 24-HDR was collected [24]. Zero consumption 
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values in the main dietary questionnaires were excluded in the regression calibration models, 
and a zero was directly imputed as a corrected value. Country and sex-specific calibration 
models were used to obtain individual predicted values of dietary exposure for all 
participants. Cox regression models were then run using the predicted (calibrated) values for 
each individual on a continuous scale and those results are considered as the main exposure in 
this study. The standard error of the calibrated coefficient was estimated with bootstrap 
sampling in the calibration and disease models and repeated 300 times [24]. 
RESULTS 
Overall, 748 subjects (666 women and 82 men) out of 467,108 participants (333,876 women 
and 142,232 men) were diagnosed with a first primary incident differentiated TC during the 
follow-up. The median (percentile 10 and 90%) of coffee consumption was 357 (16-1,000) 
mL/day and 289 (4-857) mL/day in men and women, respectively; the highest intake was in 
Denmark and the lowest ones in Italy and Spain. The median (percentile 10 and 90%) of tea 
consumption was 12 (0-625) mL/day and 14 (0-645) mL/day in men and in women, 
respectively. The highest consumption of tea in both men and women was in the UK, whereas 
the lowest consumption of tea in men and women was in Spain, Greece and Sweden (median 
≤ 1 mL/day) (Table1). 
Participants in the highest quartile of coffee consumption were more likely to be men, current 
smokers, physically active, highly educated, and to have higher intakes of alcohol and total 
energy than those in the lowest quartile. Tea consumers in the highest consumption group 
were more likely to be women, more physically active, highly educated, had lower BMI and 
waist circumference and consumed less alcohol, tobacco and total energy than non-tea 
consumers (Supplementary table 1). 
No association was observed between calibrated coffee consumption per 100mL/d and the 
risk of total differentiated TC (HRcalibrated = 1.00, 95% CI 0.97-1.04), papillary tumor 
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(HRcalibrated = 1.00, 95% CI 0.96-1.04) and follicular tumor (HRcalibrated = 1.05, 95% CI 0.96-
1.14), (P for heterogeneity =0.29) (Table 2). Similarly, null results were found between 
coffee intake, using both cohort-wide (Table 2) and country-specific quartiles (data not 
shown), and differentiated TC risk. Similar null results were observed after excluding 77 
cases who were diagnosed with differentiated TC within the first 2 years of follow-up.  
No significant association was found between calibrated tea intake per 100mL/d and the risk 
of total differentiated TC (HRcalibrated = 0.98, 95% CI 0.95-1.02). A borderline statistically 
significant heterogeneity was observed between TC site risks for tea intake (P for 
heterogeneity =0.055). No statistically association with papillary tumor (HRcalibrated = 0.99, 
95% CI 0.95-1.03) was found, whereas an inverse association was observed with follicular 
tumor risk (HRcalibrated = 0.90, 95% CI 0.81-0.99). In the sensitivity analysis after excluding 77 
cases who were diagnosed with differentiated TC within the first 2 years of follow-up, the 
results were almost identical, including the association between calibrated tea intake (per 
100mL/d) and follicular tumor risk (HRcalibrated = 0.89, 95% CI 0.79-1.00) (data not tabulated).  
The risk estimates for coffee consumption and differentiated TC were modified by BMI 
categories (BMI<25 and BMI≥25), with a positive association in subjects below BMI 25, and 
inverse associations in subjects with BMI 25 and above (p for interaction=0.009). However, 
no individual association was statistically significant in either stratum. (Supplementary table 
2). No interactions were detected by sex (p=0.72 and 0.76, respectively), tobacco (p=0.87 and 
0.48, respectively), and physical activity (p=0.34 and 0.43, respectively). 
 
DISCUSSION 
In this large prospective study, we observed no association between both coffee or tea 
consumption and overall differentiated TC risk in either men or women, or for either papillary 
or follicular tumors. 
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Similarly to our findings, in a recent meta-analysis of 7 epidemiological studies, including 
only 2 prospective cohorts (including 109 and 159 TC cases), no association between coffee 
intake and TC risk was found [12]. Authors of the meta-analysis recommended further 
prospective studies on this topic evaluating potential differences between sexes, histological 
subtypes and coffee types, and estimating dose-response relationships. We were able to 
investigate most of these issues, since the number of TC cases in our cohort was more than 4-
fold larger than the previous prospective studies [25,26]. Our study shows null results in both 
men and women, as well as in either papillary or follicular tumors. Indeed, the results were 
not statistically significant using either quartiles or the continuous variable. The collection of 
data on caffeinated and decaffeinated coffee was limited to a few EPIC centers, which 
hampers statistical power for these analyses and therefore our ability to draw any conclusions 
on possible associations. To our knowledge, only one population-based case-control study 
reported separate association estimates for caffeinated and decaffeinated coffee with TC, 
showing null results for both associations [27]. Moreover, in Europe, coffee brewing methods 
vary greatly among countries, with Northern populations drinking large quantities of diluted 
coffee, and Southern populations principally consuming concentrated coffee, such as 
espressos. Despite the fact that we did not collect data on brewing method, which could have 
varied by country, no association between coffee and TC risk was observed using country-
specific quartiles. 
In the present study, no association was found between tea consumption, which in Europe is 
mostly black tea, and overall differentiated TC risk. In 2015, a meta-analysis of 11 studies, 
including only one cohort study (including 159 TC cases), showed an inverse association 
between tea intake and overall TC risk for the highest versus the lowest category of tea 
consumption (risk estimate = 0.77, 95% CI 0.62-0.97) [11]. This association was, however, 
only detected in the case-control studies, that are more prone to recall bias. In the subgroup 
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analysis by geographic locations, the association was statistically significant only in the US-
based studies; however, it was not confirmed in a recent US cohort: the Prostate, Lung, 
Colorectal, and Ovarian Cancer Screening Trial (PLCO) prospective study [25]. Regarding 
histological subtypes, no association was observed with papillary TC risk in our study; 
whereas an inverse association was detected with follicular TC risk (using the continuous 
variable but not the categorical one). Cellular and animal experiments have shown protective 
effects of tea constituents, particularly flavonoids, against TC [15]. Despite the biological 
plausibility of an inverse association between tea consumption and TC risk and the potential 
etiological differences between papillary and follicular TC, it is important to bear in mind that 
in our study the number of follicular cancer cases is rather low (n=109) and this may be the 
result of multiple comparisons and sub-set analyses. Therefore, the results were probably due 
to chance. Unfortunately, there was no data on the relationship by histological subtypes in the 
meta-analysis [11]. Hence, further prospective studies are warranted to evaluate this 
relationship between tea consumption and follicular TC risk.  
Major strengths of our study were its prospective design, the long follow-up, and its large 
sample size with a relatively high number of TC cases. However, our study had some 
limitations. Firstly, our results may be influenced by measurement errors in the dietary 
assessment that may have attenuated our findings; although we partially controlled them using 
validated country-specific dietary questionnaire [20] and calibrating the associations using the 
24-HDR [24]. Secondly, diet was only assessed at baseline, and that any potential dietary 
changes during follow-up are unaccounted for. In addition, coffee data on brewing method 
was not collected; although differences in brewing methods are larger in participants from 
different countries than in participants in the same country. Results were almost identical 
using either cohort-wide or country-specific quartiles of coffee consumption. Moreover, 
limited data on coffee type (caffeinated or decaffeinated coffee) and no data on tea type 
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(green, black, white or oolong tea) was available in this study. In addition, some individuals 
may have modified their diet during the early prediagnostic period of the disease, but 
sensitivity analyses excluding incident cases diagnosed in the first 2 years of follow-up did 
not alter the risk estimates. Finally, we have adjusted our models for several potential 
confounders, although the presence of possible residual confounding cannot be excluded. 
In conclusion, no association between coffee and tea consumption and the risk of overall 
differentiated TC was found in this large multi-center European cohort. Null results were also 
observed between coffee intake and both papillary and follicular TC risk. For tea 
consumption, our study shows no association and an inverse association with papillary and 
follicular TC risk, respectively, but these sub-analyses’ findings should be interpreted with 
caution. Future studies capturing coffee brewing methods, using nutritional biomarkers [26] 
and repeated measurements of coffee and tea intake during the follow-up might further 
develop our understanding of the association between tea and coffee consumption and TC 
risk. 
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Table 1. Number of differentiated TC cases and median (10th-90th percentile) of coffee and tea intake by sex and country in the EPIC study. 
Country 
Women   Men 
N 
Cancer cases 
Coffee (mL/d) Tea (mL/d) 
  
N 
Cancer cases 
Coffee (mL/d) Tea (mL/d) TC Papillary Follicular NOS   TC Papillary Follicular NOS 
France 67,391 248 227 19 2 225 (0-616) 26 (0-564)   - - - - - - - 
Italy 30,511 106 81 16 9 90 (0-184) 5 (0-150)   14,032 21 16 3 2 90 (30-180) 3 (0-150) 
Spain 24,846 74 62 11 1 100 (0-300) 0 (0-0)   15,138 6 4 2 0 75 (0-232) 0 (0-0) 
United 
Kingdom 52,565 39 24 10 5 217 (4-857) 475 (2-1140)   22,850 5 5 0 0 475 (4-857) 475 (2-1140) 
The 
Netherlands 26,910 13 10 3 0 500 (125-875) 238 (4-619)   9,627 4 2 1 1 625 (125-1125) 119 (0-475) 
Greece 15,229 28 22 1 5 140 (5-340) 0 (0-11)   10,815 8 6 0 2 170 (33-420) 0 (0-11) 
Germany 27,373 67 47 18 2 342 (52-784) 24 (0-401)   21,178 15 11 3 1 392 (41-900) 21 (0-398) 
Sweden 26,365 29 20 4 5 385 (107-750) 0 (0-250)   22,301 10 5 3 2 400 (108-829) 1 (0-250) 
Denmark 28,714 26 18 8 0 900 (86-1300) 157 (0-900)   26,291 13 10 3 0 900 (200-1600) 29 (0-900) 
Norway 33,972 36 31 4 1 360 (60-780) -   - - - - - - - 
TOTAL 333,876 666 542 94 30 289 (4-857) 14 (0-645)   142,232 82 59 15 8 357 (16-1000) 12 (0-625) 
Abbreviations: TC thyroid cancer, NOS not otherwise specified 
 
24 
 
Table 2. Hazard ratios (HR) and 95% confidence intervals (CI) for differentiated thyroid cancer (TC), and subtypes, according to quartile of 
intake of coffee and tea in the EPIC study. 
 
1
Tea was classified as group 1: non-consumers; group 2-4: tertiles of tea consumers 
Model 1: stratified by center, age at baseline (1-year interval) and sex. 
Model 2: additionally adjusted for body mass index, smoking status, education level, physical activity, total energy and alcohol intake. In 
women, also adjusted for menopause status and type, oral contraceptive use, and infertility problems. 
 
 
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI) HR (95% CI)
Coffee
Quartile 1 241 1.00 (ref) 1.00 (ref) 197 1.00 (ref) 1.00 (ref) 31 1.00 (ref) 1.00 (ref)
Quartile 2 209 0.85 (0.70-1.03) 0.86 (0.71-1.04) 173 0.87 (0.70-1.07) 0.87 (0.71-1.08) 24 0.74 (0.43-1.28) 0.74 (0.43-1.28)
Quartile 3 158 0.92 (0.74-1.16) 0.93 (0.75-1.17) 126 0.90 (0.70-1.15) 0.90 (0.70-1.16) 24 1.12 (0.60-2.08) 1.15 (0.62-2.14)
Quartile 4 140 1.01 (0.80-1.29) 1.01 (0.79-1.29) 105 0.95 (0.73-1.25) 0.95 (0.72-1.26) 30 1.51 (0.81-2.81) 1.48 (0.78-2.80)
P-trend 0.69 0.72 0.85 0.85 0.09 0.11
Observed continuous (per 100mL/d) 1.01 (0.99-1.04) 1.01 (0.99-1.04) 1.01 (0.98-1.04) 1.01 (0.98-1.04) 1.06 (0.99-1.12) 1.05 (0.99-1.12) 0.21
Calibrated continuous (per 100mL/d) 1.01 (0.97-1.04) 1.00 (0.97-1.04) 1.00 (0.96-1.04) 1.00 (0.96-1.04) 1.05 (0.97-1.14) 1.05 (0.96-1.14) 0.29
Tea
1
Group 1 278 1.00 (ref) 1.00 (ref) 219 1.00 (ref) 1.00 (ref) 45 1.00 (ref) 1.00 (ref)
Group 2 154 1.11 (0.88-1.38) 1.12 (0.89-1.40) 117 1.11 (0.86-1.43) 1.12 (0.87-1.44) 25 0.82 (0.47-1.44) 0.85 (0.48-1.48)
Group 3 193 1.18 (0.96-1.45) 1.20 (0.97-1.47) 165 1.29 (1.03-1.62) 1.30 (1.04-1.64) 21 0.58 (0.33-1.03) 0.60 (0.34-1.08)
Group 4 87 0.91 (0.68-1.22) 0.93 (0.70-1.25) 69 1.00 (0.73-1.37) 1.01 (0.73-1.39) 14 0.50 (0.23-1.06) 0.52 (0.24-1.13)
P-trend 0.39 0.46 0.88 0.92 0.12 0.10
Observed continuous (per 100mL/d) 0.98 (0.95-1.01) 0.98 (0.95-1.01) 0.99 (0.96-1.03) 0.99 (0.96-1.03) 0.90 (0.81-0.99) 0.90 (0.82-0.99) 0.029
Calibrated continuous (per 100mL/d) 0.98 (0.95-1.02) 0.98 (0.95-1.02) 0.99 (0.95-1.03) 0.99 (0.95-1.03) 0.90 (0.81-0.99) 0.90 (0.81-0.99) 0.055
Differentiated TC Papillary tumour Follicular tumour
P for 
heterogeneity
N of 
cases
N of 
cases
N of 
cases
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Supplementary table 1. Baseline characteristics by quartile of coffee and tea consumption in the EPIC study. 
    Coffee   Tea
3
 
  Q1 
(n=118,982) 
Q2 
(n=117,671) 
Q3 
(n=119,423) 
Q4 
(n=120,032)   
G1 
(n=149,783) 
G2 
(n=94,184) 
G3 
(n=100,694) 
G4 
(n=97,475) 
Cutoffs (mg/d) <94 94-299 300-540 >540   0 >0-42 43-428 >428 
Sex, women (%) 72.7 71.3 71.6 64.9   66.5 61.4 72.7 71.1 
Country (%)                   
  France 16.1 17.9 14.5 8.2   18.4 9.2 20.9 10.4 
  Italy 20.6 16.5 0.5 <0.1   13.4 12.9 11.9 0.4 
  Spain 16.9 14.0 2.4 0.4   25.6 0.3 1.2 0.1 
  UK 18.9 12.9 17.8 13.8   1.4 11.8 10.0 53.5 
  The Netherlands 2.7 4.4 10.0 13.5   2.6 5.3 18.9 9.0 
  Greece 7.5 10.4 3.4 0.7   8.0 13.7 1.1 <0.1 
  Germany 5.2 11.8 12.0 11.8   7.8 18.3 14.8 4.9 
  Sweden 3.3 6.4 17.4 13.7   17.0 11.7 9.6 2.5 
  Denmark 4.7 3.2 12.5 25.6   5.9 16.8 11.6 19.1 
  Norway 4.1 2.4 9.6 12.3           
Age (y) 50.6 (10.8) 51.3 (10.1) 51.6 (9.9) 51.4 (8.8)   52.7 (8.8) 50.0 (10.4) 50.4 (10.0) 52.0 (11.8) 
Body mass index (kg/m
2
) 25.5 (4.6) 25.6 (4.4) 25.1 (4.1) 25.5 (4.1)   26.3 (4.5) 25.7 (4.3) 24.9 (4.1) 24.7 (3.9) 
Waist circumference (cm) 85.2 (13.3) 85.5 (13.0) 84.2 (12.7) 86.0 (12.9)   88.2 (13.0) 85.8 (13.2) 83.5 (12.5) 81.8 (12.2) 
Total energy (kcal/d) 2052 (623) 2107 (624) 2025 (594) 2117 (631)   2149 (636) 2086 (642) 2101 (616) 2072 (575) 
Alcohol (g/d) 10.5 (16.9) 12.3 (17.6) 11.8 (16.1) 13.3 (17.6)   13.6 (19.8) 12.9 (17.7) 12.1 (15.8) 11.5 (15.2) 
Smoking status (%)
1
                   
  Never 60.2 52.7 48.7 34.4   49.1 47.7 52.1 51.8 
  Former 23.3 25.0 29.2 29.0   23.2 25.6 27.3 31.3 
  Current 14.5 20.3 19.7 35.0   26.1 25.0 18.9 14.8 
Education level (%)
1
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  Primary 36.0 35.2 22.9 26.0   47.9 29.8 20.9 14.6 
  Secondary 56.7 61.4 73.3 71.4   50.9 67.7 76.5 75.1 
Physical activity (%)
1
                   
  Inactive 61.0 59.5 50.0 45.3   63.8 54.9 49.8 52.1 
  Active 38.0 39.5 48.0 51.5   35.6 44.1 47.5 45.7 
Menopause status (%)
1,2
                   
  Premenopausal 38.8 37.8 32.1 30.2   31.0 39.9 35.2 35.4 
  Perimenopausal 16.3 16.7 20.7 23.1   46.7 41.6 42.8 46.4 
  Postmenopausal 41.4 42.3 44.8 44.4   18.7 15.6 19.3 15.0 
  Surgical menopause 3.6 3.2 2.4 2.3   3.6 3.0 2.8 3.2 
Oral contraceptive use (%)
1,2
                 
  No 48.4 45.6 36.7 33.8   52.6 41.7 34.8 34.1 
  Yes 51.7 54.4 63.3 66.2   47.4 58.3 65.2 65.9 
Infertility problems (%)
1,2
                   
  No 94.9 95.4 95.6 95.7   95.2 95.6 95.4 95.2 
  Yes 5.1 4.6 4.4 4.3   4.8 4.4 4.6 4.8 
Values are means and standard deviations. 
1
Missing values: smoking status 9,676 (2.03%), education level 16,929 (3.56%), physical activity 8,824 (1.85%), oral contraceptive use 8,427 
(2.52%), infertility problems 111,162 (33.29%). 
2
Variables only available in women. 
3
Tea was classified as group 1: non-consumers; group 2-4: tertiles of tea consumers 
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Supplementary table 2. Hazard ratios (HR) and 95% confidence intervals (CI) for differentiated thyroid cancer (TC) stratified by body mass 
index (BMI) according to consumption of coffee and tea in the EPIC study. 
    BMI<25   BMI≥25 
P for 
interaction 
    N of 
cases 
Model 1 Model 2   N of 
cases 
Model 1 Model 2 
    HR (95% CI) HR (95% CI)   HR (95% CI) HR (95% CI) 
Coffee                 
  Quartile 1 115 1.00 (ref) 1.00 (ref)   126 1.00 (ref) 1.00 (ref)   
  Quartile 2 99 0.88 (0.67-1.15) 0.88 (0.67-1.16)   110 0.80 (0.61-1.04) 0.80 (0.61-1.05)   
  Quartile 3 101 1.16 (0.87-1.56) 1.17 (0.87-1.57)   57 0.64 (0.45-0.91) 0.64 (0.45-0.92)   
  Quartile 4 81 1.27 (0.92-1.75) 1.25 (0.90-1.74)   59 0.70 (0.48-1.01) 0.70 (0.48-1.02)   
  P-trend   0.058 0.074     0.058 0.066 0.009 
  Observed continuous (per 100mL/d) 1.04 (1.01-1.08) 1.04 (1.01-1.08)     0.97 (0.93-1.01) 0.97 (0.93-1.01)   
  Calibrated continuous (per 100mL/d) 1.04 (0.99-1.09) 1.04 (0.99-1.09)     0.96 (0.91-1.01) 0.96 (0.91-1.01)   
Tea                 
 
Quartile 1 132 1.00 (ref) 1.00 (ref)   146 1.00 (ref) 1.00 (ref)   
  Quartile 2 72 0.96 (0.70-1.31) 0.96 (0.70-1.31)   82 1.29 (0.93-1.79) 1.30 (0.93-1.81)   
  Quartile 3 114 1.04 (0.79-1.36) 1.04 (0.80-1.37)   79 1.42 (1.03-1.97) 1.44 (1.04-1.99)   
  Quartile 4 55 0.84 (0.59-1.20) 0.85 (0.59-1.21)   32 1.04 (0.64-1.70) 1.06 (0.65-1.73)   
  P-trend   0.37 0.40     0.93 0.96 0.63 
  Observed continuous (per 100mL/d) 0.99 (0.95-1.03) 0.99 (0.95-1.03)     0.97 (0.92-1.02) 0.97 (0.92-1.02)   
  Calibrated continuous (per 100mL/d) 0.99 (0.95-1.04) 0.99 (0.95-1.04)     0.97 (0.91-1.03) 0.97 (0.91-1.03)   
Model 1: stratified by center, age at baseline (1-year interval) and sex. 
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Model 2: additionally adjusted for BMI, smoking status, education level, physical activity, total energy and alcohol intake. In women, also 
adjusted for menopause status and type, oral contraceptive use, and infertility problems. 
 
 
